"Doxorubicin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.
| Descriptor ID |
D004317
|
| MeSH Number(s) |
D02.455.426.559.847.562.050.200.175 D04.615.562.050.200.175 D09.408.051.059.200.175
|
| Concept/Terms |
Adriblastin- Adriblastin
- Adriblastine
- Adriblastina
- Adriablastine
- Adriablastin
DOXO-cell- DOXO-cell
- DOXO cell
- Urokit Doxo-cell
- Urokit Doxo cell
|
Below are MeSH descriptors whose meaning is more general than "Doxorubicin".
Below are MeSH descriptors whose meaning is more specific than "Doxorubicin".
This graph shows the total number of publications written about "Doxorubicin" by people in this website by year, and whether "Doxorubicin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 2 | 3 |
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 3 | 4 |
| 1999 | 1 | 0 | 1 |
| 2000 | 0 | 3 | 3 |
| 2001 | 0 | 2 | 2 |
| 2002 | 1 | 3 | 4 |
| 2003 | 1 | 3 | 4 |
| 2004 | 1 | 4 | 5 |
| 2005 | 0 | 5 | 5 |
| 2006 | 1 | 3 | 4 |
| 2007 | 1 | 3 | 4 |
| 2008 | 2 | 8 | 10 |
| 2009 | 2 | 8 | 10 |
| 2010 | 0 | 5 | 5 |
| 2011 | 0 | 9 | 9 |
| 2012 | 2 | 2 | 4 |
| 2013 | 0 | 8 | 8 |
| 2014 | 3 | 13 | 16 |
| 2015 | 5 | 10 | 15 |
| 2016 | 2 | 3 | 5 |
| 2017 | 3 | 4 | 7 |
| 2018 | 2 | 10 | 12 |
| 2019 | 7 | 4 | 11 |
| 2020 | 4 | 8 | 12 |
| 2021 | 2 | 6 | 8 |
| 2022 | 1 | 8 | 9 |
| 2023 | 1 | 4 | 5 |
| 2024 | 3 | 3 | 6 |
| 2025 | 2 | 3 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Doxorubicin" by people in Profiles.
-
Comparison of the Cytotoxicity, Internalization and Anti-Cancer Drug Delivery Efficacy of Nature Killer Cell Derived Nanovesicles and Extracellular Vesicles. Int J Nanomedicine. 2025; 20:10683-10700.
-
Neoadjuvant HER2-targeted regimens with or without anthracyclines for HER2-positive inflammatory breast cancer: a multicenter retrospective study. Breast Cancer Res Treat. 2025 Nov; 214(1):69-77.
-
Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a phase 2 study. Blood Adv. 2025 May 27; 9(10):2461-2472.
-
Hematology-oncology provider perspectives regarding lymphoma treatment and cardioprotective strategies in patients with lymphoma at high risk for heart failure. Leuk Lymphoma. 2025 Aug; 66(8):1437-1446.
-
Inosine monophosphate dehydrogenase 2 (IMPDH2) modulates response to therapy and chemo-resistance in triple negative breast cancer. Sci Rep. 2025 01 07; 15(1):1061.
-
Self-targeted smart polyester nanoparticles for simultaneous Delivery of photothermal and chemotherapeutic agents for efficient treatment of HCC. Biomater Sci. 2024 Dec 03; 12(24):6368-6381.
-
Stimuli Responsive Molecular Exchange of Structure Directing Agents on Gold Nanobipyramids: Cancer Cell Detection and Synergistic Therapeutics. ACS Appl Bio Mater. 2024 07 15; 7(7):4542-4552.
-
Loss of CELF2 promotes skin tumorigenesis and increases drug resistance. Int J Dermatol. 2025 Jan; 64(1):101-110.
-
Plasmablastic lymphoma: 2024 update on diagnosis, risk stratification, and management. Am J Hematol. 2024 08; 99(8):1586-1594.
-
GZ17-6.02 kills PDX isolates of uveal melanoma. Oncotarget. 2024 May 17; 15:328-344.